RegeneRx enrolls first patients in phase 3 US dry eye clinical trial with RGN-259
The primary endpoints of the ARISE-2 trial are the change in ocular discomfort and the change in inferior corneal staining at baseline (prior to first dose) and at
Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
The companies formed a clinical trial collaboration to evaluate the combination treatment. The dose-escalation part assessing IPI-549 as a monotherapy in Infinity’s phase 1 trial is continuing, and
ECHELON-2 is a global phase 3 randomized trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-positive mature T-cell